HUMMINGBIRD BIOSCIENCE Mediaroom

Hummingbird Bioscience and Dartmouth's Geisel School of Medicine to Co-Host 3rd Annual Virtual VISTA Symposium on March 27, 2024

SINGAPORE and HANOVER, Germany, March 13, 2024 /PRNewswire/ -- Hummingbird Bioscience andDartmouth'...

2024-03-13 17:00 2295

Hummingbird Bioscience to Present Two Posters on Anti-HER3 and Anti-VISTA Antibody Therapeutics at American Association for Cancer Research (AACR) Meeting 2024

* Presentations will highlight the broad potential treatment opportunities for its clinical-stage...

2024-03-06 05:30 1786

Hummingbird Bioscience Strengthens Leadership Team with Appointment of Angèle Maki as Chief Business Officer

SAN FRANCISCO and SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven pr...

2023-12-11 18:00 1369

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

* HMBD-001 is Hummingbird Bioscience's proprietary anti-HER3 antibody in Phase I/IIa trials in th...

2023-10-23 14:23 1430

Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)

Endeavor obtains exclusive worldwide rights to Hummingbird Bioscience's anti-HER3 ADC to be develop...

2023-10-19 20:18 1708

Hummingbird Bioscience to Present Poster on HMBD-001 Combination Strategy for Squamous Non-Small Cell Lung Cancer at World Conference on Lung Cancer 2023

HOUSTON and SINGAPORE, Aug. 21, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precisio...

2023-08-21 17:58 1319

Hummingbird Bioscience Initiates HMBD-001 Phase IB Trials in Australia and Partners with Omico to Accelerate Clinical Development

* Hummingbird Bioscience has initiated two clinical trials in Australia evaluating HMBD-001 in pa...

2023-07-27 04:00 1716

Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023

* HMBD-002, a non-depleting, high-affinity anti-VISTA antibody, possesses key design features ena...

2023-05-29 18:30 2709

Hummingbird Bioscience and Merck Enter Collaboration to Evaluate HMBD-001 In Squamous Non-Small Cell Lung Carcinoma

* Hummingbird Bioscience enters a clinical trial collaboration and supply agreement with Merck to...

2023-05-15 18:30 2175

Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases

* HMBD-011 is a potentially first-in-class anti-VH4-34 antibody developed for treatment of VH4-34...

2023-05-08 18:30 1967

Hummingbird Bioscience to Present Two Posters on HER3-Targeting Therapeutics at American Association for Cancer Research (AACR) Meeting 2023

* Presentations highlight the robust tumor growth inhibition in preclinical models for its HER3-t...

2023-03-15 18:30 2174

Hummingbird Bioscience Exercises Its Option to License the Clinical Trial Results from Cancer Research UK to Support Further Development of HMBD-001

SINGAPORE and LONDON, March 6, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision...

2023-03-06 21:00 1978

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program

* Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies * Synaffix ...

2023-01-04 21:00 2279

Hummingbird Bioscience Announces Two HMBD-002 Poster Presentations at the Society for Immunotherapy of Cancer 2022 Annual Meeting

* VISTA blockade with HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T-c...

2022-11-07 21:00 1641

Hummingbird Bioscience to Attend the Credit Suisse 31st Annual Healthcare Conference

SAN FRANCISCO, HOUSTON and SINGAPORE, Nov. 1, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-d...

2022-11-01 20:00 1319

Hummingbird Bioscience Holds Opening Ceremony for Singapore Science Park Office and Research Facilities

SINGAPORE, Sept. 23, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherap...

2022-09-23 17:00 1693

Hummingbird Bioscience Chief Scientific Officer Jerome Boyd-Kirkup to Present at the 2nd Annual VISTA Virtual Symposium

SINGAPORE, Sept. 19, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherap...

2022-09-19 20:00 1269

Hummingbird Bioscience Announces Trial in Progress Poster Presentation at the European Society for Medical Oncology Congress 2022

* HMBD-001 is a proprietary anti-HER3 antibody in an ongoing Phase 1 trial targeting multiple sol...

2022-09-08 20:00 1747

Hummingbird Bioscience to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

SAN FRANCISCO, Sept. 6, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biothe...

2022-09-06 20:00 2124

Hummingbird Bioscience Publishes Preclinical Data Demonstrating Therapeutic Potential of HMBD-002 in VISTA-expressing Cancers

HOUSTON and SINGAPORE, Feb. 9, 2022 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-...

2022-02-09 17:00 1512

Latest News